Vyleesi Patent Expiration and Generic Bremelanotide Timeline

How Bremelanotide Works: The MC4R Mechanism

Bremelanotide is a synthetic cyclic peptide that activates melanocortin-4 receptors (MC4R) in the central nervous system. That single sentence separates it from every other drug approved for hypoactive sexual desire disorder (HSDD). Flibanserin targets serotonin pathways. Bremelanotide works downstream of dopaminergic signaling, binding MC4R neurons in the medial preoptic area and ventromedial hypothalamus to modulate sexual arousal and desire through a pathway that is distinct from hormonal or serotonergic mechanisms 1.

The drug's peptide structure matters for the patent discussion. Peptides occupy a regulatory gray zone between small molecules and biologics. The FDA approved bremelanotide under a standard New Drug Application (NDA 210557), not a Biologics License Application (BLA), which means generic versions would follow the ANDA pathway governed by Hatch-Waxman rules rather than the biosimilar pathway under the Biologics Price Competition and Innovation Act (BPCIA) 2. This distinction directly affects how long patent protection functions as a barrier to competition.

The clinical evidence supporting the MC4R mechanism comes from the two RECONNECT trials. In pooled analysis of 1,247 premenopausal women with HSDD, bremelanotide 1.75 mg subcutaneous injection produced a statistically significant increase of 0.5 points on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 compared with placebo (P<0.001), along with a mean 1.0-point improvement on the co-primary endpoint of satisfying sexual events 1.

The Patent Portfolio Protecting Vyleesi

Palatin Technologies built its bremelanotide intellectual property over two decades. The earliest filings date to the late 1990s, when the company first characterized melanocortin receptor agonist peptides for sexual dysfunction indications.

The core composition-of-matter patents cover the cyclic heptapeptide structure of bremelanotide itself. U.S. Patent No. 8,487,073, titled "Melanocortin receptor-specific compounds," was granted in July 2013 and carries an expiration date in 2029 before any patent term adjustments 3. A continuation patent, U.S. Patent No. 9,255,123, extends coverage of specific pharmaceutical compositions containing bremelanotide through 2030. These two patents form the backbone of Vyleesi's market exclusivity.

Method-of-use patents add additional layers. Several patents in the family cover the specific subcutaneous administration route, the 1.75 mg dose selection, and the on-demand dosing regimen (no more than once every 24 hours, no more than 8 doses per month). Method-of-use patents are narrower in scope and easier for generic manufacturers to design around or challenge, but they still impose litigation risk that delays generic filings 3.

The FDA's Orange Book lists the patents associated with NDA 210557. Any generic applicant filing an ANDA must certify to each listed patent under one of four Paragraph certifications. A Paragraph IV certification, which asserts the patent is invalid or would not be infringed, triggers an automatic 30-month stay of FDA approval for the generic. That stay is the mechanism by which brand manufacturers buy time even when their patents face challenge.

No ANDA with a Paragraph IV certification has been filed against Vyleesi as of May 2026.

FDA Exclusivity Periods: What Has Already Expired

The FDA granted bremelanotide five-year new chemical entity (NCE) exclusivity upon approval in June 2019. That five-year window expired in June 2024, meaning the FDA is now permitted to accept ANDAs referencing the Vyleesi NDA 4.

NCE exclusivity is separate from patent protection. Its expiration opened the door for generic companies to begin filing, but it did not remove the patent barriers. Think of NCE exclusivity as a lock on the FDA's mailbox. The mailbox is now open. The patents are a separate set of locks on the drug itself.

Vyleesi did not receive orphan drug exclusivity (its indication is too common) or pediatric exclusivity (no pediatric studies were required or conducted for HSDD in premenopausal women). The absence of these extensions is notable because orphan exclusivity adds 7 years and pediatric exclusivity adds 6 months. Neither applies here, which modestly shortens the overall protection timeline compared to drugs that qualify for both 4.

Why No Generic Has Been Filed Yet

Three factors explain the absence of generic bremelanotide applications.

First, the commercial market is small. Vyleesi generated estimated U.S. net revenues of approximately $15 million in 2024, a fraction of what blockbuster drugs earn. Generic manufacturers prioritize filing ANDAs for drugs with large revenue bases because the cost of patent litigation, bioequivalence studies, and manufacturing setup must be justified by projected generic sales 5.

Second, peptide manufacturing presents technical barriers. Bremelanotide is a cyclic heptapeptide synthesized via solid-phase peptide synthesis, a process that requires specialized equipment and quality controls beyond standard small-molecule manufacturing. The bioequivalence requirements for peptide generics are also more complex, often requiring comparative pharmacokinetic studies with tighter acceptance criteria.

Third, the autoinjector device adds a formulation and device layer. A generic applicant would need to demonstrate pharmaceutical equivalence for both the drug product and the delivery device. This increases development costs and regulatory complexity.

These factors make bremelanotide a low-priority target for the generic industry. The drug's niche market, combined with its remaining patent coverage through 2030, creates a situation where generic companies have little financial incentive to invest in an ANDA.

Realistic Timeline for Generic Availability

Based on current patent expirations, market dynamics, and the absence of any ANDA filing, the earliest realistic date for a generic bremelanotide is 2031. Here is the reasoning.

The core composition patent (U.S. 9,255,123) expires in 2030. Even if a generic manufacturer filed a Paragraph IV challenge tomorrow, the 30-month stay would push any approval to late 2028 at the earliest, and that assumes the challenger prevails in patent litigation, which historically happens in roughly 48% of Hatch-Waxman cases according to an FTC analysis of settlements from 2004 to 2020 6.

A more likely scenario: a generic manufacturer waits for key patents to expire and files a Paragraph III certification (which concedes patent validity and simply waits). Under this approach, the ANDA could not be approved until the last relevant patent expires. Filing in 2028, with a 24-to-30-month FDA review timeline for a peptide ANDA, would yield an approval in 2030 to 2031.

The 180-day first-filer exclusivity under Hatch-Waxman would give the first generic entrant six months of market exclusivity before additional competitors could enter 4. During that six-month window, prices typically drop 20% to 30%. After multiple generics enter, historical data from peptide drugs like octreotide show price reductions of 50% to 70% within 18 months.

What a Generic Would Mean for Patients

Vyleesi's current average wholesale price exceeds $950 per single-dose autoinjector. At a recommended maximum of 8 doses per month, the theoretical maximum monthly cost is approximately $7,600 before insurance. Most patients use 2 to 4 doses per month, placing typical out-of-pocket costs at $200 to $500 per month with commercial insurance, or significantly higher without coverage.

A generic bremelanotide could reduce per-dose costs by 50% to 70% based on precedent from other peptide generics. Octreotide (Sandostatin LAR) saw its price fall roughly 60% within two years of generic entry in 2020. A comparable reduction would bring bremelanotide autoinjector costs to approximately $300 to $475 per unit, or $75 to $190 per month for a patient using 2 to 4 doses 7.

Insurance coverage patterns could also shift with generic entry. Payers who currently exclude Vyleesi from formularies due to cost may add generic bremelanotide to preferred tiers. As of 2025, an estimated 40% of commercial health plans did not cover Vyleesi, according to formulary analyses. Generic availability could expand access significantly for the estimated 6 million premenopausal women in the U.S. who meet diagnostic criteria for HSDD 8.

How Bremelanotide Compares to Flibanserin on Patent Status

Flibanserin (Addyi), the only other FDA-approved drug for premenopausal HSDD, already has a generic available. The FDA approved the first generic flibanserin in 2022 after key patents expired. Generic flibanserin 100 mg tablets now cost approximately $30 to $80 per month, compared with roughly $400 per month for brand Addyi 9.

This comparison matters for two reasons. First, it demonstrates that HSDD drug generics are commercially viable even in a niche market when the price gap is large enough. Second, it suggests that patients and prescribers may favor flibanserin on cost alone until generic bremelanotide becomes available, despite the two drugs having entirely different mechanisms and dosing schedules.

Bremelanotide offers on-demand dosing (as needed, 45 minutes before anticipated activity). Flibanserin requires daily administration. The RECONNECT trials showed bremelanotide improved desire and reduced distress with on-demand use, while flibanserin's VIOLET and DAISY trials required 4 to 8 weeks of daily dosing before clinical effect 1. For patients who prefer event-based treatment, bremelanotide remains the only option regardless of cost.

Potential Regulatory Pathway Changes That Could Accelerate Access

The FDA has signaled increasing interest in complex generic drug programs for peptides. In 2023, the agency released updated guidance on demonstrating bioequivalence for peptide drug products, which could lower the regulatory bar for bremelanotide generics 10.

505(b)(2) applications represent another route. A 505(b)(2) NDA allows a manufacturer to rely partially on the FDA's previous findings for the reference drug while submitting new clinical or nonclinical data. This pathway could support a bremelanotide product in a different device (such as a prefilled syringe instead of an autoinjector) or a different concentration 2.

Patent term extensions under 35 U.S.C. 156 could theoretically extend Palatin's protection. However, patent term restoration applies only to one patent per product and is limited to the time lost during FDA review. Bremelanotide's review period was standard (a 10-month review cycle), so any extension would be modest, likely adding 1 to 2 years at most 3.

Covis Pharma and the Current Commercial Situation

AMAG Pharmaceuticals originally held the U.S. commercialization rights for Vyleesi. After AMAG was acquired by Covis Pharma Group in 2020, Vyleesi's commercial strategy shifted toward a specialty pharmacy distribution model with direct-to-patient shipping. Covis has maintained a patient savings program that caps out-of-pocket costs at $50 per dose for commercially insured patients, though eligibility restrictions apply 2.

Palatin Technologies retains the underlying patents and has publicly stated interest in pursuing additional melanocortin receptor agonist compounds. Their pipeline includes MC1R-targeted agents for inflammatory conditions, which share structural similarities with bremelanotide but target different receptor subtypes. Any new melanocortin patents filed by Palatin would not extend bremelanotide's own patent coverage, though they could create freedom-to-operate concerns for generic manufacturers working with related peptide structures.

The commercial situation for Vyleesi is unusual: low revenue, high per-unit cost, and a manufacturer (Covis) that acquired it as part of a larger portfolio deal rather than as a priority asset. This profile does not attract aggressive generic competition. The drug exists in a space where patients need it, access is limited by cost, and the market dynamics that typically accelerate generic entry are muted.

Clinicians prescribing bremelanotide should counsel patients that generic alternatives are unlikely before 2031, that the Covis savings program may reduce immediate costs, and that flibanserin generics offer a lower-cost (though mechanistically different) alternative for HSDD in the interim.